Print Page | Sign In | Join
News & Press
Filter news by category:

Read about recent events, essential information and the latest community news.

Displaying page 10 of 27
 |<   <<   <  5  |  6  |  7  |  8  |  9  |  10  |  11  |  12  |  13  |  14  |  15  >   >>   >| 

Scientific Advancements
Monday, November 14, 2022   (0 Comments - view/add)
Heru Continues to Revolutionize Vision Care, Surpassing Clinical Milestone of 100,000 Eyes Examined »
Heru Continues to Revolutionize Vision Care, Surpassing Clinical Milestone of 100,000 Eyes Examined...
Thursday, November 10, 2022   (0 Comments - view/add)
Longeveron Announces Completion of Enrollment in Phase 2a Trial of Lomecel-B™ for the Treatment of A »
Longeveron Announces Completion of Enrollment in Phase 2a Trial of Lomecel-B™ for the Treatment of Alzheimer’s Disease...
Tuesday, October 18, 2022   (0 Comments - view/add)
Cyclo Therapeutics Announces Publication of Phase 1 Data for Trappsol® Cyclo™ for the Treatment of N »
Cyclo Therapeutics Announces Publication of Phase 1 Data for Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Ty...
Tuesday, October 18, 2022   (0 Comments - view/add)
Unique human neuromuscular junction assay establishes skeletal muscle as a key player in ALS »
Unique human neuromuscular junction assay establishes skeletal muscle as a key player in ALS...
Friday, October 14, 2022   (0 Comments - view/add)
Todos Medical advances Tollovir™: 3CL Clinical Trials to Phase 2 »
Todos Medical advances Tollovir™: 3CL Clinical Trials to Phase 2 October 14, 2022 14:23...
Tuesday, October 4, 2022   (0 Comments - view/add)
Cyclo Therapeutics Commences Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer »
Cyclo Therapeutics Commences Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer’s Disease Oct 4, 20...
Thursday, September 29, 2022   (0 Comments - view/add)
InflammX Therapeutics Submits IND Amendment to Enable Clinical Studies with Orally Dosed Xiflam™, i »
InflammX Therapeutics Submits IND Amendment to Enable Clinical Studies with Orally Dosed Xiflam™, its NLRP3 Inflammasome...
Thursday, September 29, 2022   (0 Comments - view/add)
Catalyst Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application for FIRDAPSE® E »
Catalyst Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application for FIRDAPSE® Expanding Patient P...
Wednesday, September 28, 2022   (0 Comments - view/add)
KemPharm Announces Positive Topline Data from Phase 1 Clinical Trial Evaluating Cardiovascular Safet »
KemPharm Announces Positive Topline Data from Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylpheni...
Tuesday, September 27, 2022   (0 Comments - view/add)
Ambulero Receives Positive Pre-IND Response from FDA for AMB-301 Treatment of Rare Vascular Disease »
Ambulero Receives Positive Pre-IND Response from FDA for AMB-301 Treatment of Rare Vascular Disease...
Friday, September 23, 2022   (0 Comments - view/add)
Demand for the Direct Care Healthcare Model Continues to Grow »
New Healthcare Model Gains in Popularity TAMPA, Fla. ,  Sept. 23, 2022  /PRNewswire/ -- With the desire for...
Saturday, September 17, 2022   (0 Comments - view/add)
MagicTouch SCB receives IDE approval for In-Stent Restenosis indication »
MagicTouch SCB receives IDE approval for In-Stent Restenosis indication TAMPA, Fla. , Sept. 17, 2022 /PRNewswire...
Tuesday, September 13, 2022   (0 Comments - view/add)
Dyadic Updates Market on Recent Scientific Achievements »
Dyadic Updates Market on Recent Scientific Achievements September 13, 2022 08:00 ET...
Wednesday, August 31, 2022   (0 Comments - view/add)
FDA Authorizes Moderna, Pfizer-BioNTech Bivalent COVID-19 Vaccines for Use as a Booster Dose »
FDA Authorizes Moderna, Pfizer-BioNTech Bivalent COVID-19 Vaccines for Use as a Booster Dose For Immediate Releas...
Wednesday, August 31, 2022   (0 Comments - view/add)
U.S. Food and Drug Administration (FDA) Grants Fast Track Designation for Longeveron’s Lomecel-B™ Pr »
U.S. Food and Drug Administration (FDA) Grants Fast Track Designation for Longeveron’s Lomecel-B™ Product for Treatmen...
Wednesday, August 31, 2022   (0 Comments - view/add)
Segal Trials Participation in Study Shows Positive Results From Phase 3 EMERGENT-2 KarXT in Schizoph »
Miami-Based Clinical Trial Company  Plays Pivotal Role In Karuna Therapeutics Submitting New Drug Application to t...
Tuesday, August 30, 2022   (0 Comments - view/add)
UF Researchers Use AI To Predict New Coronavirus Variants »
UF Researchers Use AI To Predict New Coronavirus Variants A world awash in waves of novel coronavirus variants is left to...
Monday, August 29, 2022   (0 Comments - view/add)
Longeveron Receives Intent to Grant Notice from the European Patent Office for Methods to Monitor »
MIAMI, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company devel...
Thursday, August 18, 2022   (0 Comments - view/add)
AIM ImmunoTech Announces Commencement of Phase 2 Study of Ampligen® for the Treatment of Pancreatic »
AIM ImmunoTech Announces Commencement of Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer...
Tuesday, August 16, 2022   (0 Comments - view/add)
VySpine Announces FDA Clearance for VyPlate Anterior Cervical Plate System »
VySpine Announces FDA Clearance for VyPlate Anterior Cervical Plate System...
Thursday, August 11, 2022   (0 Comments - view/add)
Pasithea Therapeutics Announces Results of Preclinical Study Demonstrating Tolerizing Vaccine Effica »
Pasithea Therapeutics Announces Results of Preclinical Study Demonstrating Tolerizing Vaccine Efficacy in Relapsing-Re...
Wednesday, August 10, 2022   (0 Comments - view/add)
Psilera's New Compounds Show Potential for Significant Treatment Improvement in Depression and Neuro »
Psilera's New Compounds Show Potential for Significant Treatment Improvement in Depression and Neurodegenerative Disorders...
Wednesday, August 3, 2022   (0 Comments - view/add)
ZyVersa's Proprietary Inflammasome ASC Inhibitor's Differentiated Mechanism of Action Featured in Tr »
ZyVersa's Proprietary Inflammasome ASC Inhibitor's Differentiated Mechanism of Action Featured in Translational Research P...
Thursday, July 28, 2022   (0 Comments - view/add)
AIM ImmunoTech Reports Positive Pilot Study Data from Expanded Access Program Evaluating Ampligen® f »
AIM ImmunoTech Reports Positive Pilot Study Data from Expanded Access Program Evaluating Ampligen® for the Treatment o...
Thursday, July 28, 2022   (0 Comments - view/add)
Redwire to Develop Space-Based Drug Development and Manufacturing Platform »
Redwire to Develop Space-Based Drug Development and Manufacturing Platform...
Thursday, July 28, 2022   (0 Comments - view/add)
Lenstec SBL-3 multifocal intraocular lens for cataract surgery approved by FDA for sale in the US »
Lenstec SBL-3 multifocal intraocular lens for cataract surgery approved by FDA for sale in the US Lenstec Inc. has anno...
Thursday, July 28, 2022   (0 Comments - view/add)
Nilogen Oncosystems Announces Opening of Clinical Trial Using Ex Vivo Tumoroids to Predict Immunothe »
Nilogen Oncosystems Announces Opening of Clinical Trial Using Ex Vivo Tumoroids to Predict Immunotherapy Response in Non...
Monday, July 18, 2022   (0 Comments - view/add)
Stuart Therapeutics Announces Successful Outcome from Type C Meeting with FDA »
Stuart Therapeutics Announces Successful Outcome from Type C Meeting with FDA STUART, Fla. , July 18, 2022 /PRNe...
Monday, July 18, 2022   (0 Comments - view/add)
Ultragenyx and GeneTx Provide Program Update on GTX-102 for Angelman Syndrome Including Promising In »
ULTRAGENYX AND GENETX PROVIDE PROGRAM UPDATE ON GTX-102 FOR ANGELMAN SYNDROME INCLUDING PROMISING INTERIM DATA FROM PHASE...
Thursday, July 14, 2022   (0 Comments - view/add)
Exactech Announces Successful First Surgeries with Latest Instrumentation for Its Newton™ Balanced »
Exactech Announces Successful First Surgeries with Latest Instrumentation for Its Newton™ Balanced Knee Technology...
Wednesday, July 13, 2022   (0 Comments - view/add)
Coronavirus (COVID-19) Update: FDA Authorizes Emergency Use of Novavax COVID-19 Vaccine, Adjuvanted »
Coronavirus (COVID-19) Update: FDA Authorizes Emergency Use of Novavax COVID-19 Vaccine, Adjuvanted For Immediate...
Friday, July 1, 2022   (0 Comments - view/add)
Neurotech Startup Canaery Secures Over $4 Million in Seed Funding to Digitize the Sense of Smell »
Neurotech Startup Canaery Secures Over $4 Million in Seed Funding to Digitize the Sense of Smell...
Thursday, June 30, 2022   (0 Comments - view/add)
INSIGHTEC RECEIVES FDA IDE APPROVAL FOR PROSTATE CANCER COMPARATIVE STUDY USING HIGH INTENSITY FOCUS »
INSIGHTEC RECEIVES FDA IDE APPROVAL FOR PROSTATE CANCER COMPARATIVE STUDY USING HIGH INTENSITY FOCUSED ULTRASOUND TECHNOLO...
Thursday, June 23, 2022   (0 Comments - view/add)
INSIGHTEC Announces Peer Reviewed Publication of Phase 2b Focused Ultrasound Prostate Cancer Study i »
INSIGHTEC ANNOUNCES PEER REVIEWED PUBLICATION OF PHASE 2B FOCUSED ULTRASOUND PROSTATE CANCER STUDY IN THE LANCET ONCOLOG...
Thursday, June 16, 2022   (0 Comments - view/add)
Cordis Announces Successful First-in-Human Use of the Radianz Radial Peripheral System™ »
Cordis Announces Successful First-in-Human Use of the Radianz Radial Peripheral System™ Successful procedures initiate...

Displaying page 10 of 27
 |<   <<   <  5  |  6  |  7  |  8  |  9  |  10  |  11  |  12  |  13  |  14  |  15  >   >>   >| 

About BioFlorida

BioFlorida is the voice of Florida's life sciences industry, representing 8,600 establishments and research organizations in the BioPharma, MedTech, Digital Health and Health Systems that collectively employ nearly 107,000 Floridians. Source: TEConomy/BIO (released 2022)